Liver cancer is known as the "silent killer"—its early symptoms are concealed, and by the time of diagnosis, it has often progressed to the middle or advanced stages, missing the optimal window for intervention.
Although traditional surgery, radiotherapy, and chemotherapy can control tumor progression in the short term, they have limitations such as insufficient targeting, significant toxic side effects, and a high likelihood of tumor relapse and metastasis.
Although emerging therapies such as CAR-T have demonstrated promising efficacy in hematologic malignancies, they have repeatedly encountered setbacks in liver cancer treatment due to insufficient infiltration.
The point came during a museum visit...
We encountered a bronze vessel adorned with the gluttonous “taotie (a mythical beast from ancient Chinese mythology and folklore)” motif, symbolizing greed and desire, which reminded us once again of the ferocity of liver cancer.
The docent explained, "The “taotie” devours all things..." "Isn't that just like macrophages!" blurted out one team member.
In that instant, a brilliant idea emerged: using macrophages as the blade to directly target liver cancer!
Months later, in a laboratory petri dish, the first macrophage bearing the codename
Inspired by the symmetry of the “taotie” motif on ancient bronze vessels, we designed a targeting receptor and constructed a dual-signaling pathway.
Through carefully designed functional components, we ensure that after SYNERGY enters the human body, it will only be activated in the liver, which greatly reduces the risk of off-target.
On one hand, The activated SYNERGY can enhance its own phagocytic ability against tumor cells.
On the other hand, they reprogram themselves into an M1-type polarization state with anti-tumor functions, synergistically killing liver cancer.
